首页> 美国卫生研究院文献>Journal of Ophthalmology >Evaluation of the Safety and Effectiveness of Intense Pulsed Light in the Treatment of Meibomian Gland Dysfunction
【2h】

Evaluation of the Safety and Effectiveness of Intense Pulsed Light in the Treatment of Meibomian Gland Dysfunction

机译:强脉冲光治疗睑板腺功能不全的安全性和有效性评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purpose. This study aims to explore the safety and efficacy of a novel treatment-intense pulsed light (IPL) in MGD eyes. Methods. This study is a prospective and open label study. Forty eyes of 40 MGD patients were recruited in the study and received 4 consecutive IPL treatments on day 1, day 15, day 45, and day 75. Ten ocular surface symptoms were evaluated with a subjective face score at every visit. Best spectacle corrected visual acuity, intraocular pressure (IOP), conjunctival injection, upper and lower tear meniscus height (TMH), tear break-up time (TBUT), corneal staining, lid margin and meibomian gland assessments, and meibography were also recorded at every visit, as well as the adverse effects on the eye and ocular surface. Results. Significant improvements were observed in single and total ocular surface symptom scores, TBUT, and conjunctival injection at all the visits after the initial IPL treatment (P < 0.05). Compared to baseline, the signs of eyelid margin, meibomian gland secretion quality, and expressibility were significantly improved at every visit after treatments. There was no regional and systemic threat observed in any patient. Conclusion. Intense pulsed light (IPL) therapy is a safe and efficient treatment in relieving symptoms and signs of MGD eyes.
机译:目的。这项研究旨在探讨新型治疗强脉冲光(IPL)在MGD眼睛中的安全性和有效性。方法。这项研究是一项前瞻性和开放性研究。在该研究中招募了40名MGD患者的40只眼,并在第1天,第15天,第45天和第75天接受了4次连续IPL治疗。每次访视时都会对10种眼表症状进行主观面部评分评估。最佳眼镜矫正视力,眼压(IOP),结膜注射,上,下泪液半月板高度(TMH),泪液破裂时间(TBUT),角膜染色,眼睑边缘和睑板腺评估以及睑板造影也记录在案以及每次对眼睛和眼表的不良影响。结果。在初次IPL治疗后的所有就诊中,单眼和总眼表症状评分,TBUT和结膜注射均有显着改善(P <0.05)。与基线相比,治疗后每次访视时眼睑边缘,睑板腺分泌质量和可表达性的迹象均得到显着改善。在任何患者中均未观察到区域性和全身性威胁。结论。强脉冲光(IPL)治疗是缓解MGD眼睛症状和体征的安全有效方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号